UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

NCT00083551 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

668

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Thalidomide
DRUG: Ara-C
DRUG: BCNU
DRUG: Cisplatin
DRUG: Cytoxan
DRUG: Dexamethasone
DRUG: Doxorubicin
DRUG: Etoposide
DRUG: Filgrastim
DRUG: Recombinant GM-CSF
DRUG: Interferon-alpha-2b
DRUG: Melphalan
DRUG: Vincristine

Sponsor

University of Arkansas

Collaborators

[object Object]